دورية أكاديمية
أعرض في EDS

Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.

التفاصيل البيبلوغرافية
العنوان: Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
المؤلفون: Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.; Department of Gastroenterology, Takarazuka City Hospital, Hyogo, Japan., Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan., Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan., Kariyama K; Department of Hepatology, Okayama City Hospital, Okayama, Japan., Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan., Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan., Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan., Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan., Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Gunma, Japan., Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan., Tada F; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan., Tanaka H; Department of Gastroenterology, Takarazuka City Hospital, Hyogo, Japan., Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan., Nouso K; Department of Hepatology, Okayama City Hospital, Okayama, Japan., Tanaka K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan., Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
مؤلفون مشاركون: Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
المصدر: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2024 Jul; Vol. 39 (7), pp. 1394-1402. Date of Electronic Publication: 2024 Apr 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Scientific Publications Country of Publication: Australia NLM ID: 8607909 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1746 (Electronic) Linking ISSN: 08159319 NLM ISO Abbreviation: J Gastroenterol Hepatol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Melbourne ; Boston : Blackwell Scientific Publications, c1986-
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/virology , Carcinoma, Hepatocellular*/mortality , Antiviral Agents*/therapeutic use , Liver Neoplasms*/virology , Liver Neoplasms*/mortality , Sustained Virologic Response*, Humans ; Aged ; Male ; Retrospective Studies ; Female ; Middle Aged ; Japan ; Treatment Outcome ; Prognosis ; Hepatitis C/drug therapy ; Hepatitis C/complications ; Age Factors ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/complications ; Hepacivirus ; Survival Rate ; East Asian People
مستخلص: Background and Aim: Direct-acting antivirals (DAAs) have been accessible in Japan since 2014. The aim of this study is to compare how the prognosis of patients with hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCV-HCC) changed before and after DAA development.
Methods: A retrospective analysis of 1949 Japanese HCV-HCC patients from January 2000 to January 2023 categorized them into pre-DAA (before 2013, n = 1169) and post-DAA (after 2014, n = 780) groups. Changes in clinical features and prognosis were assessed.
Results: Despite no significant differences in BCLC stage between groups, the post-DAA group exhibited higher rates of sustained virological response (SVR) (45.6% vs. 9.8%), older age (73 vs 69 years), lower levels of AST (40 vs 56 IU/L), ALT (31 vs 46 IU/L), and AFP (11.7 vs 23.6 ng/mL), higher platelet count (13.5 vs 10.8 × 10 4 /μL), better prothrombin time (88.0% vs 81.9%), and better ALBI score (-2.54 vs -2.36) (all P < 0.001). The post-DAA group also showed higher rates of curative treatments (74.1% vs 65.2%) and significantly improved recurrence-free survival (median 2.8 vs 2.1 years). Adjusted for inverse probability weighting, overall survival was superior in the post-DAA group (median 7.4 vs 5.6 years, P < 0.001). Subanalysis within the post-DAA group revealed significantly shorter overall survival for patients without SVR (median 4.8 years vs NA vs NA) compared to pre-SVR or post-SVR patients (both P < 0.001). No significant difference in OS was observed between the pre-SVR and post-SVR groups (P = 1.0).
Conclusion: The development of DAA therapy has dramatically improved the prognosis of HCV-HCC patients.
(© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
References: Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022; 400: 1345–1362.
Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA initiation after curative treatment and its relationship with the recurrence of HCV‐related hCC. J. Hepatocell. Carcinoma 2020; 7: 347–360.
Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675.
Chung RT, Baumert TF. Curing chronic hepatitis C—the arc of a medical triumph. N. Engl. J. Med. 2014; 370: 1576–1578.
Drafting Committee for Hepatitis Management Guidelines tJSoH. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol. Res. 2020; 50: 791–816.
Bourlière M, Gordon SC, Flamm SL et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N. Engl. J. Med. 2017; 376: 2134–2146.
Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–1130.
Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka hepatocellular carcinoma prevention study group. Ann. Intern. Med. 1998; 129: 94–99.
Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka liver disease study group. Hepatology 1998; 27: 1394–1402.
Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann. Intern. Med. 1999; 131: 174–181.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck‐Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta‐analysis of observational studies. Ann. Intern. Med. 2013; 158: 329–337.
Mettke F, Schlevogt B, Deterding K et al. Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment. Pharmacol. Ther. 2018; 47: 516–525.
Reig M, Mariño Z, Perelló C et al. Unexpected high rate of early tumor recurrence in patients with HCV‐related HCC undergoing interferon‐free therapy. J. Hepatol. 2016; 65: 719–726.
Toyoda H, Kumada T, Tada T et al. The impact of HCV eradication by direct‐acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study. Liver Int. 2019; 39: 448–454.
Li DK, Ren Y, Fierer DS et al. The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: an ERCHIVES study. Hepatology 2018; 67: 2244–2253.
Nagata H, Nakagawa M, Asahina Y et al. Effect of interferon‐based and ‐free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J. Hepatol. 2017; 67: 933–939.
Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378–390.
Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet 2017; 389: 56–66.
Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‐inferiority trial. Lancet 2018; 391: 1163–1173.
Finn RS, Qin S, Ikeda M et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 2020; 382: 1894–1905.
Abou‐Alfa GK, Lau G, Kudo M et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022; 1.
Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358–380.
Hiraoka A, Michitaka K, Kumada T et al. Validation and potential of albumin‐bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017; 6: 325–336.
Reig M, Forner A, Rimola J et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 2022; 76: 681–693.
Hiraoka A, Kumada T, Michitaka K et al. Usefulness of albumin‐bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016; 31: 1031–1036.
Harimoto N, Yoshizumi T, Sakata K et al. Prognostic significance of combined albumin‐bilirubin and tumor‐node‐metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma. Hepatol. Res. 2017; 47: 1289–1298.
Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J. Gastroenterol. 2003; 38: 207–215.
Pugh RN, Murray‐Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646–649.
Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence‐based approach‐the ALBI grade. J. Clin. Oncol. 2015; 33: 550–558.
Kokudo N, Takemura N, Hasegawa K et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update. Hepatol. Res. 2019; 49: 1109–1113.
Kanda Y. Investigation of the freely available easy‐to‐use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452–458.
Verna EC, Morelli G, Terrault NA et al. DAA therapy and long‐term hepatic function in advanced/decompensated cirrhosis: real‐world experience from HCV‐TARGET cohort. J. Hepatol. 2020; 73: 540–548.
Enomoto M, Ikura Y, Tamori A et al. Short‐term histological evaluations after achieving a sustained virologic response to direct‐acting antiviral treatment for chronic hepatitis C. United European Gastroenterol. J. 2018; 6: 1391–1400.
Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C‐related hepatocellular carcinoma: a systematic review and meta‐analysis. Int. J. Cancer 2017; 140: 1042–1049.
Nagaoki Y, Imamura M, Nishida Y et al. The impact of interferon‐free direct‐acting antivirals on clinical outcome after curative treatment for hepatitis C virus‐associated hepatocellular carcinoma: comparison with interferon‐based therapy. J. Med. Virol. 2019; 91: 650–658.
Ochi H, Hiraoka A, Hirooka M et al. Direct‐acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J. Gastroenterol. 2021; 56: 90–100.
Mashiba T, Joko K, Kurosaki M et al. Does interferon‐free direct‐acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital liver study group. PLoS ONE 2018; 13: e0194704.
Toyoda H, Hiraoka A, Uojima H et al. Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response. Hepatol. Commun. 2021; 5: 1290–1299.
Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon‐based antiviral therapy. Hepatol. Res. 2015; 45: 152–161.
Makiyama A, Itoh Y, Kasahara A et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 1616–1622.
Ikeda M, Fujiyama S, Tanaka M et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J. Gastroenterol. 2005; 40: 148–156.
Tokita H, Fukui H, Tanaka A et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J. Gastroenterol. Hepatol. 2005; 20: 752–758.
Hung CH, Lee CM, Wang JH et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy. Int. J. Cancer 2011; 128: 2344–2352.
Arase Y, Kobayashi M, Suzuki F et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964–973.
Calvaruso V, Cabibbo G, Cacciola I et al. Incidence of hepatocellular carcinoma in patients with HCV‐associated cirrhosis treated with direct‐acting antiviral agents. Gastroenterology 2018; 155: 411–421.e4.
Yasui Y, Kurosaki M, Komiyama Y et al. Wisteria floribunda agglutinin‐positive Mac‐2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct‐acting antivirals for hepatitis C virus. Hepatol. Res. 2018; 48: 1131–1139.
Watanabe T, Tokumoto Y, Joko K et al. Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection. Hepatol. Res. 2019; 49: 136–146.
Hiraoka A, Kumada T, Ogawa C et al. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after direct acting antivirals: multicenter analysis. J. Gastroenterol. Hepatol. 2019; 34: 436–441.
Tada T, Kurosaki M, Tamaki N et al. A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response. JGH Open. 2022; 6: 20–28.
فهرسة مساهمة: Keywords: direct‐acting antivirals; hepatitis C virus; hepatocellular carcinoma
المشرفين على المادة: 0 (Antiviral Agents)
تواريخ الأحداث: Date Created: 20240411 Date Completed: 20240712 Latest Revision: 20240712
رمز التحديث: 20240712
DOI: 10.1111/jgh.16553
PMID: 38602340
قاعدة البيانات: MEDLINE
الوصف
تدمد:1440-1746
DOI:10.1111/jgh.16553